BriaCell (BCTX) Therapeutics announces its Phase 3 clinical study has screened over 230 and enrolled over 160 patients. BriaCell anticipates reporting topline data as early as 1H2026. Interim data will be analyzed once 144 patient events occur. Positive results from this pivotal study could support full approval and marketing authorization of Bria-IMT in patients with metastatic breast cancer. BriaCell’s pivotal Phase 3 clinical study is evaluating BriaCell’s lead clinical candidate, Bria-IMT, plus an immune check point inhibitor versus physician’s choice in advanced metastatic breast cancer
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCTX:
- BriaCell Unveils Promising Clinical Data at 2025 SABCS
- BriaCell to present Phase 2 survival, Phase 3 data at SABCS 2025
- BriaCell announces publication with preliminary Phase 1b expansion cohort data
- BriaCell Therapeutics to Present Promising Clinical Data at SABCS 2025
- BriaCell and Receptor.AI Collaborate on AI-Driven Cancer Therapeutics